DERICK MOODY: Open Payments
NPI 1235551409 · SPRINGVILLE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,069 in 105 payments from 14 companies in 2025. Trend: 2023 $1,672 · 2024 $1,908 · 2025 $2,069
Food & beverage: $2,069
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $299 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $189 |
| Neurocrine BioSciences, Inc. | 8 | $180 |
| Teva Pharmaceuticals USA, Inc. | 15 | $172 |
| Supernus Pharmaceuticals, Inc. | 6 | $171 |
| E.R. Squibb & Sons, L.L.C. | 11 | $156 |
| Alkermes, Inc. | 3 | $144 |
| Janssen Pharmaceuticals, Inc | 5 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
Products named: VRAYLAR, CAPLYTA, TRINTELLIX, REXULTI, INGREZZA, Qelbree, AUSTEDO XR, COBENFY.
Industry payments across UT — which companies pay providers there.
